Get the Daily Brief
Latest Biotech News
St. Jude unveils CHANGE‑seq‑BE: a rapid safety assay for base editors
Scientists at St. Jude Children’s Research Hospital developed CHANGE‑seq‑BE, an unbiased, sensitive method to map genome‑wide off‑target activity induced by base editors. Reported in Nature...
Inhalable bispecific exosomes reprogram T cells – activity in ICI‑resistant melanoma
A Nature Biotechnology paper described engineered inhalable exosomes carrying a bispecific T‑cell activator that, when delivered to the lung, activated antitumor T cells and suppressed...
Deep Intelligent Pharma Raises $50M — AI to automate clinical trials
Singapore-based Deep Intelligent Pharma (DIP) closed a $50 million Series D to scale an AI-driven platform that automates clinical trial design, execution and regulatory-readiness. The company...
Insilico and Servier Ink $888M Oncology Pact — AI discovery scales
AI drug-discovery company Insilico Medicine signed a multiyear R&D collaboration with French pharma Servier worth up to $888 million to jointly discover and develop oncology candidates using...
Sanofi doubles down on AI biologics — repeat pacts with Earendil
Sanofi expanded its relationship with AI-driven biologics developer Earendil Labs through a new agreement worth up to $160 million in near-term checks, adding to a prior Sanofi–Earendil pact that...
Wegovy pill launches in U.S. — pricing and access front and center
Novo Nordisk began shipping an oral formulation of semaglutide (Wegovy pill) in the U.S.; the company and pharmacies reported immediate dispensing for patients with prescriptions. The oral product...
Sanofi to buy Dynavax for $2.2B — adds HEPLISAV‑B and shingles candidate
Sanofi agreed to acquire Dynavax Technologies for approximately $2.2 billion in cash, a deal that adds the approved two-dose adult hepatitis B vaccine HEPLISAV‑B and a Phase I/II shingles vaccine...
Zenas’ phase III win in IgG4‑RD sinks stock — investors eye cross‑trial read
Zenas Biopharma reported positive Phase III Indigo results for obexelimab in immunoglobulin G4‑related disease (IgG4‑RD), meeting the primary endpoint with a 56% reduction in flare risk versus...
Moderna seeks approvals for mRNA flu vaccine — regulatory push for respiratory franchise
Moderna filed regulatory applications in the U.S., EU, Canada and Australia for its mRNA seasonal influenza vaccine mRNA‑1010, targeting adults aged 50 and older. The company pitched faster design...
CRISPR–Cas3 enables long deletions to silence TTR in vivo — new gene‑editing route
Researchers reported CRISPR–Cas3 genome editing as an alternative to Cas9 for transthyretin (TTR) amyloidosis, using Cas3 to generate long-range deletions that abolished TTR expression. In vitro...
CHANGE‑seq‑BE profiles base‑editor off‑targets — safety tool adopted for emergency FDA case
St. Jude Children’s Research Hospital developed CHANGE‑seq‑BE, an unbiased and resource‑efficient genome‑wide method to map off‑target activity of base editors. The team published the method in...
Inhalable bispecific exosomes activate T cells — preclinical reversal of PD‑1 resistance
A Nature Biotechnology paper described engineered inhalable exosomes that deliver a bispecific T‑cell activator into the tumor microenvironment to treat pembrolizumab‑resistant metastatic melanoma...
Deep Intelligent Pharma Raises $50M – AI to automate clinical trials
Deep Intelligent Pharma (DIP) closed a $50 million Series D round to scale an AI platform that its founders say automates clinical trial design and execution. The Singapore-based company will use...
Moderna seeks approval for mRNA flu shot: mRNA-1010 filed globally
Moderna filed regulatory applications in the US, EU, Canada and Australia seeking approval of mRNA‑1010, its seasonal influenza vaccine for people 50 and older. The company pitched the shot as a...
Sanofi to buy Dynavax for $2.2B: Adds Hep B vaccine and shingles candidate
Sanofi agreed to acquire Dynavax Technologies for roughly $2.2 billion in cash to bolster its adult immunization portfolio. The deal, approved by Dynavax’s board, values shares at $15.50 each and...
Sanofi doubles down on Earendil – $160M pact for AI‑designed bispecifics
Sanofi struck a new collaboration with AI‑driven biologics developer Earendil Labs, committing up to $160 million in upfront and near‑term payments to apply Earendil’s predictive protein modeling...
Zenas’ obexelimab clears Phase 3 endpoint – market punishes outcome
Zenas Biopharma reported that obexelimab met the primary endpoint in a Phase 3 trial for IgG4‑related disease, delivering a statistically significant reduction in flares versus placebo. The...
CRISPR–Cas3 enables large deletions and 80% serum TTR knockdown in mouse model
Researchers demonstrated CRISPR–Cas3 as a distinct genome‑editing modality for transthyretin (TTR) amyloidosis, producing long directional deletions that abolished TTR expression in vitro and...
Inhalable bispecific exosomes activate T cells – new approach for ICI‑resistant tumors
Two teams published complementary advances engineering inhalable exosome platforms that deliver bispecific T‑cell activators to resistant tumors. Reports in Nature Biotechnology show inhalable,...
Salus Biomed’s rapid clinical sequencer cleared by China NMPA
Salus Biomed obtained Category III medical device registration from China’s NMPA for its Saluseq Nimbo rapid next‑generation sequencer, clearing the platform for clinical applications in China....